Humana Inc.


Market Cap$40.33B

Compare Humana

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Humana Inc.Humana Inc.20.31.05%12%0.40.8
marketMarket Avg54.31.27%32%-1.3
HealthcareHealthcare Avg39.11.36%17%7.21.3

Earnings Call Q4 2023

January 25, 2024 - AI Summary

Humana reported disappointing results for the fourth quarter of 2023, with higher-than-expected utilization trends impacting the Medicare Advantage sector.
The company expects the higher costs seen in the fourth quarter to persist throughout 2024 and has prudently assumed this in their initial outlook for adjusted EPS of approximately $16 for 2024.
Looking ahead to 2025, Humana is evaluating Medicare Advantage pricing actions and expects earnings growth in other lines of business, as well as ongoing productivity and trend mitigation initiatives. They anticipate $6 to $10 of adjusted EPS growth in 2025, with any outperformance in 2024 being additive to this initial outlook.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

2% downsideHumana Target Price DetailsTarget Price

Current Fair Value

4.5% downside

Overvalued by 4.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$40.33 Billion
Enterprise Value$53.87 Billion
Dividend Yield$3.5282 (1.05%)
Earnings per Share$16.14
Outstanding Shares120,500,635
Avg 30 Day Volume1,687,736


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio20.26
Price to Sales0.39
Price to Book Ratio2.67
Enterprise Value to Revenue0.49
Enterprise Value to EBIT15.57
Enterprise Value to Net Income27
Total Debt to Enterprise0.25
Debt to Equity0.84

Revenue Sources

No data

ESG Score

No data

About Humana Inc.

CEO: Bruce Broussard